BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline Associated Disturbances of Cardiovascular Homeostasis. Curr Probl Cardiol 2021;:100909. [PMID: 34167841 DOI: 10.1016/j.cpcardiol.2021.100909] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Dantas D, Pereira AG, Fujimori ASS, Ribeiro APD, de Almeida Silva CCV, Monte MG, Corrêa CR, Fernandes AA, Bazan SGZ, Azevedo PS, Minicucci MF, de Paiva SAR, Zornoff LAM, Polegato BF. Doxycycline Attenuates Doxorubicin-Induced Cardiotoxicity by Improving Myocardial Energy Metabolism in Rats. JCDD 2022;9:254. [DOI: 10.3390/jcdd9080254] [Reference Citation Analysis]
2 Avagimyan AA, Kakturskiy LV. Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia. SJCEM 2022;37:105-111. [DOI: 10.29001/2073-8552-2022-37-2-105-111] [Reference Citation Analysis]
3 Avagimyan AA. Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide. Sibirskij nauchnyj medicinskij zhurnal 2022;42:41-46. [DOI: 10.18699/ssmj20220304] [Reference Citation Analysis]
4 Avagimyan A, Kaktursky L. CARDIOTOXICITY OF CYCLOPHOSPHAMIDE: CURRENT STATE OF THE PROBLEM. jecm 2022. [DOI: 10.52340/jecm.2022.03.14] [Reference Citation Analysis]
5 Avagimyan AA, Mkrtchyan LG, Kononchuk NB, Kaktursky LV, Agati L. Chemotherapy as a possible trigger for the myocardial lipomatosis development. Arter gipertenz 2022;27:706-712. [DOI: 10.18705/1607-419x-2021-27-6-706-712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Avagimyan A. THE PATHOPHYSIOLOGICAL BASIS OF DIABETIC CARDIOMYOPATHY DEVELOPMENT. Current Problems in Cardiology 2022. [DOI: 10.1016/j.cpcardiol.2022.101156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Avagimyan A, Gvianishvili T, Gogiashvili L, Kakturskiy L, Sarrafzadegan N, Aznauryan A. Chemotherapy, hypothyroidism and oral dysbiosis as a novel risk factor of cardiovascular pathology development. Curr Probl Cardiol 2021;:101051. [PMID: 34800544 DOI: 10.1016/j.cpcardiol.2021.101051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Avagimyan AA, Mkrtchyan LH, Gevorkyan AA, Kononchuk NB, Kakturskiy LV, Djndoyan ZT. Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case. Racionalʹnaâ farmakoterapiâ v kardiologii 2021;17:785-91. [DOI: 10.20996/1819-6446-2021-10-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Sukiasyan L. Fructose-Induced Alteration of the Heart and Vessels Homeostasis. Curr Probl Cardiol 2021;:101013. [PMID: 34637847 DOI: 10.1016/j.cpcardiol.2021.101013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Avagimyan A, Mkrtchyan L, Abrahomovich O, Sheibani M, Guevorkyan A, Sarrafzadegan N, Kozhukhov S, Agati L, Astengiano R, Zaritska V, Jndoyan Z. AC-Mode of Chemotherapy as a Trigger of Cardiac Syndrome X: A Case Study. Curr Probl Cardiol 2021;:100994. [PMID: 34571104 DOI: 10.1016/j.cpcardiol.2021.100994] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Avagimyan A, Sukiasyan L, Kakturskiy L, Mkrtchyan L, Chavushyan V, Chelidze K, Ionov A, Pavluchenko I. Diabefit as a Modifier of Fructose-induced Impairment of Cardio-vascular System. Curr Probl Cardiol 2021;:100943. [PMID: 34313227 DOI: 10.1016/j.cpcardiol.2021.100943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]